tradingkey.logo
tradingkey.logo
Search

Catheter Precision Inc

VTAK
Add to Watchlist
0.761USD
-0.011-1.49%
Close 05/15, 16:00ETQuotes delayed by 15 min
2.05MMarket Cap
LossP/E TTM

Catheter Precision Inc

0.761
-0.011-1.49%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-1.49%

5 Days

-8.32%

1 Month

-14.90%

6 Months

-60.83%

Year to Date

-58.42%

1 Year

-86.19%

Key Insights

Catheter Precision Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 153 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 38.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Catheter Precision Inc's Score

Industry at a Glance

Industry Ranking
153 / 206
Overall Ranking
431 / 4482
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Catheter Precision Inc Highlights

StrengthsRisks
Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 85.29% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 819.00K.
Undervalued
The company’s latest PE is -0.05, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 304.48K shares, increasing 43.06% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.89.

Analyst Rating

Based on 0 analysts
--
Current Rating
38.000
Target Price
+1753.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Catheter Precision Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Catheter Precision Inc Info

Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.
Ticker SymbolVTAK
CompanyCatheter Precision Inc
CEOJenkins (David A)
Websitehttps://www.ramed.com/
KeyAI